• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Millendo Therapeutics, Inc. (Amendment)

    4/13/21 10:06:27 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care
    Get the next $MLND alert in real time by email
    SC 13D/A 1 nea15-millendo_18489.htm NEW ENTERPRISE ASSOCIATES 15, L.P. / MILLENDO THERAPEUTICS, INC. -- SCHEDULE 13D/A(#1) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Millendo Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    60040X103

    (CUSIP Number)

    Louis S. Citron, Esq.

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    March 29, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 60040X103

    13D Page 2 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 15, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☒

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,766,407 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,766,407 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,766,407 shares1

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

    1Includes only shares directly held by New Enterprise Associates 15, L.P New Enterprise Associates 15, L.P. may be deemed to be part of a voting group and may be deemed to have beneficial ownership of the shares held by such voting group. See Item 4 and Item 5.

     

     

     

     

    CUSIP No. 60040X103

    13D Page 3 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 15, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☒

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,766,407 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,766,407 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,766,407 shares1

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

    1Includes only shares directly held by New Enterprise Associates 15, L.P New Enterprise Associates 15, L.P. may be deemed to be part of a voting group and may be deemed to have beneficial ownership of the shares held by such voting group. See Item 4 and Item 5.

      

     

     

     

     CUSIP No. 60040X103

    13D Page 4 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA 15 GP, LLC

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☒

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Liability Company

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,766,407 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,766,407 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,766,407 shares1

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     

    1Includes only shares directly held by New Enterprise Associates 15, L.P New Enterprise Associates 15, L.P. may be deemed to be part of a voting group and may be deemed to have beneficial ownership of the shares held by such voting group. See Item 4 and Item 5.

     

     

     

      CUSIP No. 60040X103

    13D Page 5 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Forest Baskett

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☒

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,766,407 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,766,407 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,766,407 shares1

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

    1Includes only shares directly held by New Enterprise Associates 15, L.P New Enterprise Associates 15, L.P. may be deemed to be part of a voting group and may be deemed to have beneficial ownership of the shares held by such voting group. See Item 4 and Item 5.

     

     

     

     

    CUSIP No. 60040X103

    13D Page 6 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☒

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,766,407 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,766,407 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,766,407 shares1

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

    1Includes only shares directly held by New Enterprise Associates 15, L.P New Enterprise Associates 15, L.P. may be deemed to be part of a voting group and may be deemed to have beneficial ownership of the shares held by such voting group. See Item 4 and Item 5.

     

     

     

     

    CUSIP No. 60040X103

    13D Page 7 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Mohamad H. Makhzoumi

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☒

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,766,407 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

        1,766,407 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

        1,766,407 shares1

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

    1Includes only shares directly held by New Enterprise Associates 15, L.P New Enterprise Associates 15, L.P. may be deemed to be part of a voting group and may be deemed to have beneficial ownership of the shares held by such voting group. See Item 4 and Item 5.

     

     

     

    CUSIP No. 60040X103

    13D Page 8 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☒

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,766,407 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,766,407 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,766,407 shares1

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

    1Includes only shares directly held by New Enterprise Associates 15, L.P New Enterprise Associates 15, L.P. may be deemed to be part of a voting group and may be deemed to have beneficial ownership of the shares held by such voting group. See Item 4 and Item 5.

     

     

     

    CUSIP No. 60040X103

    13D Page 9 of 18 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Peter W. Sonsini

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☒

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,766,407 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,766,407 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,766,407 shares1

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

    1Includes only shares directly held by New Enterprise Associates 15, L.P New Enterprise Associates 15, L.P. may be deemed to be part of a voting group and may be deemed to have beneficial ownership of the shares held by such voting group. See Item 4 and Item 5.

     

     

     

    CUSIP No. 60040X103

    13D Page 10 of 18 Pages    

    Item 1.  Security and Issuer.

    This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D amends and supplements the statement on 13D originally filed on December 18, 2018 relating to the common stock, par value $0.001 per share (the “Common Stock”), of Millendo Therapeutics, Inc. (f/k/a Ovascience, Inc.), a Delaware corporation (the “Issuer”) having its principal executive office at 110 Miller Avenue, Suite 100, Ann Arbor, MI 48104, United States.

     

    Item 2.  Identity and Background.

    This statement is being filed by:

     

    (a) New Enterprise Associates 15, L.P. (“NEA 15”); NEA Partners 15, L.P. (“NEA Partners 15”), which is the sole general partner of NEA 15; and NEA 15 GP, LLC (“NEA 15 LLC” and, together with NEA Partners 15, the “Control Entities”), which is the sole general partner of NEA Partners 15; and

     

    (b) Forest Baskett (“Baskett”), Anthony A Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Joshua Makower (“Makower”), Scott D. Sandell (“Sandell”) and Peter W. Sonsini (“Sonsini”) (together, the “Managers”) and Peter J. Barris (“Barris”) and David M. Mott (“Mott”). The Managers are the managers of NEA 15 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of NEA 15, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Makhzoumi, Makower and Sonsini is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10001.

     

    The principal business of NEA 15 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 15 is to act as the sole general partner of NEA 15. The principal business of NEA 15 LLC is to act as the sole general partner of NEA Partners 15. The principal business of each of the Managers is to manage the Control Entities, and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 15 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 15 and NEA Partners 15 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

     

     

     

    CUSIP No. 60040X103

    13D Page 11 of 18 Pages    

     

     

     

    Item 4.  Purpose of Transaction.

    On March 29, 2021, the Issuer, Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of the Issuer (“Merger Sub”), and Tempest Therapeutics, Inc., a Delaware corporation (“Tempest”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Tempest, with Tempest continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the “Merger”). In connection with, and as a condition to, the closing of the transactions contemplated by the Merger Agreement, the Issuer and Tempest entered into a Public Company Support Agreement (the “Voting Agreement”) with NEA 15 and certain other shareholders of the Issuer (collectively, the “Shareholders”) pursuant to which the Shareholders committed to vote the shares of Common Stock that each Shareholder owns in favor of (i) issuance of the shares of the Issuer’s common stock issuable in connection with the Merger under the rules of The Nasdaq Stock Market LLC and (ii) amendment of the Issuer’s certificate of incorporation to effect a reverse split of the Issuer’s common stock at a ratio of between 1:10 and 1:15, as determined by a committee of the Issuer’s board of directors prior to the closing of the Merger (the “Public Company Voting Proposals”). The Voting Agreement will terminate the earlier of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof or (b) the date on which the Public Company Voting Proposals shall have been approved by the requisite shareholders.

     

    As a result of the Voting Agreement, the Reporting Persons may be deemed to be members of a “group” with the parties to the Voting Agreement.[1]

     

    The foregoing description of the Voting Agreement is qualified in its entirety by reference to the Voting Agreement, which is attached as Exhibit 10.2 to the Issuer’s Form 8-K filed with the Securities and Exchange Commission (“SEC”) on March 29, 2021 and incorporated herein by reference.

     

    NEA 15 acquired the NEA 15 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 15 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

     

    (a)The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

     

    (b)An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

     

    (c)A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

     

    (d)Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

    (e)Any material change in the present capitalization or dividend policy of the Issuer;

     

    (f)Any other material change in the Issuer’s business or corporate structure;

     

    (g)Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

     

    (h)Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i)A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

     

    (j)Any action similar to any of those enumerated above.


    1See the Schedule 13D or 13G (or an amendment thereto to the extent any material change in the facts set forth in any Schedule 13D or 13G previously filed by any other Shareholder has occurred) filed, or that the Reporting Persons anticipate will be filed, separately by each Shareholder, which includes, or will include, information regarding the other Shareholder’s jurisdiction of organization, principal business and address of principal office.

     

     

     

     

    CUSIP No. 60040X103

    13D Page 12 of 18 Pages    

      

     Item 5.  Interest in Securities of the Issuer.

    (a)NEA 15 is the record owner of the NEA 15 Shares. As the general partner of NEA 15, NEA Partners 15 may be deemed to own beneficially the NEA 15 Shares. As the sole general partner of NEA Partners 15, NEA 15 LLC may be deemed to own beneficially the NEA 15 Shares. As members of NEA 15 LLC, each of the Managers may be deemed to own beneficially the NEA 15 Shares.

     

    Each Reporting Person disclaims beneficial ownership of the NEA 15 Shares and the shares held by the other Shareholders other than those shares which such person owns of record.

     

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on the 19,043,034 shares of Common Stock reported to be outstanding as of March 15, 2021 on the Issuer’s Form 10-K, filed with the SEC on March 29, 2021.

     

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)

    Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

     

    (d)

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Shares beneficially owned by any of the Reporting Persons.

     

    (e)

    Each of Barris and Mott has ceased to beneficially own five percent (5%) or more of the Issuer’s Common Stock as a result of ceasing to be a Manager of NEA 15 LLC.

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    The information provided and incorporated by reference in Item 4 is hereby incorporated by reference. 

     

    Item 7.  Material to Be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

    CUSIP No. 60040X103

    13D Page 13 of 18 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 13th day of April, 2021.

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:

    NEA PARTNERS 15, L.P.

    General Partner

     

    By:

    NEA 15 GP, LLC

    General Partner

      

      By:          *                                

     Louis S. Citron

     Chief Legal Officer 

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:          *                                

    Louis S. Citron

    Chief Legal Officer 

     

      

    NEA 15 GP, LLC

     

    By:          *                                

    Louis S. Citron

    Chief Legal Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 60040X103

    13D Page 14 of 18 Pages    

     

     

     

     

     

                     *                        

    Peter J. Barris

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    David M. Mott

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

     

     

     

    */s/ Sasha O. Keough           

    Sasha O. Keough

    As attorney-in-fact

     

    This Amendment No. 1 to Schedule 13D was executed by Sasha O. Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     
     

     

    CUSIP No. 60040X103

    13D Page 15 of 18 Pages    

     

    EXHIBIT 1

     

     

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Millendo Therapeutics, Inc.

     

    EXECUTED this 13th day of April, 2021.

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:

    NEA PARTNERS 15, L.P.

    General Partner

     

    By:

    NEA 15 GP, LLC

    General Partner

      

      By:          *                                

    Louis S. Citron

    Chief Legal Officer

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:          *                                

    Louis S. Citron

    Chief Legal Officer

     

      

    NEA 15 GP, LLC

     

    By:          *                                

    Louis S. Citron

    Chief Legal Officer

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 60040X103

    13D Page 16 of 18 Pages    

     

     

     

     

     

                     *                        

    Peter J. Barris

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    David M. Mott

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

     

     

    */s/ Sasha O. Keough           

    Sasha O. Keough

    As attorney-in-fact

    This Agreement relating to Schedule 13D was executed by Sasha O. Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

    CUSIP No. 60040X103

    13D Page 17 of 18 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett            

    M. James Barrett

     

    /s/ Peter J. Barris                

    Peter J. Barris

     

    /s/ Forest Baskett                

    Forest Baskett

     

    /s/ Ali Behbahani                 

    Ali Behbahani

     

    /s/ Colin Bryant                   

    Colin Bryant

     

    /s/ Carmen Chang               

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher          

    Carol G. Gallagher

     

    /s/ Dayna Grayson               

    Dayna Grayson

     

    /s/ Patrick J. Kerins             

    Patrick J. Kerins

     

    /s/ P. Justin Klein                

    P. Justin Klein

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 60040X103

    13D Page 18 of 18 Pages    

     

     

     

     

    /s/ Vanessa Larco               

    Vanessa Larco

     

    /s/ Joshua Makower             

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers         

    Edward T. Mathers

     

    /s/ David M. Mott                

    David M. Mott

     

    /s/ Sara M. Nayeem            

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos    

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta          

    Chetan Puttagunta

     

    /s/ Jon Sakoda                     

    Jon Sakoda

     

    /s/ Scott D. Sandell              

    Scott D. Sandell

     

    /s/ A. Brooke Seawell          

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini             

    Peter W. Sonsini

     

    /s/ Melissa Taunton             

    Melissa Taunton

     

    /s/ Frank M. Torti                

    Frank M. Torti

     

    /s/ Ravi Viswanathan           

    Ravi Viswanathan

     

    /s/ Paul E. Walker               

    Paul E. Walker

     

    /s/ Rick Yang                      

    Rick Yang

     

      

    Get the next $MLND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLND

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest and Millendo Announce Stockholder Approval of Merger

    SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. ("Tempest"), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (NASDAQ:MLND) ("Millendo"), announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June 22, 2021. The stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies. The closing of the merger is anticipated to take place on or around Friday, June 25, 2021. Following the closin

    6/22/21 4:00:00 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    Tempest and Millendo Announce Proposed Merger Agreement

    SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Tempest Therapeutics, Inc. (“Tempest”), a privately-held clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today that they have entered into a definitive agreement under which Millendo will merge with Tempest in an all-stock transaction. The combined company will focus on advancing Tempest’s oncology pipeline of small molecule therapeutics that have the potential to address a wide range of tumors. Upon shareholder approval, the combined company is expected to

    3/29/21 7:00:00 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    $MLND
    SEC Filings

    View All

    Millendo Therapeutics, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    7/7/21 5:18:29 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form 8-K/A filed by Millendo Therapeutics, Inc. (Amendment)

    8-K/A - Millendo Therapeutics, Inc. (0001544227) (Filer)

    7/1/21 4:44:35 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    Millendo Therapeutics, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Millendo Therapeutics, Inc. (0001544227) (Filer)

    6/28/21 8:51:29 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    $MLND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: Versant Venture Capital VI, L.P. claimed ownership of 2,176,411 units of Common Stock

    3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/6/21 6:26:38 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Xu Stella

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/6/21 6:05:53 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Woiwode Thomas

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/6/21 6:01:21 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    $MLND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Millendo Therapeutics, Inc.

    SC 13G - Tempest Therapeutics, Inc. (0001544227) (Subject)

    7/8/21 4:25:45 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Millendo Therapeutics, Inc.

    SC 13G - Tempest Therapeutics, Inc. (0001544227) (Subject)

    7/6/21 10:59:33 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Millendo Therapeutics, Inc. (Amendment)

    SC 13D/A - Millendo Therapeutics, Inc. (0001544227) (Subject)

    4/13/21 10:06:27 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care